AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

Foralumab stabilized disability for 6 months in all 10 people with nonactive SPMS who took part in an expanded access program, a study found.

Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), likely contributing to the persistent inflammation characteristic of the ...

Multiple sclerosis (MS) is best known for the physical symptoms it can cause, such as numbness, weakness, spasticity, and difficulty walking. But this autoimmune disease of the central nervous system ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...